deltatrials
Completed NA INTERVENTIONAL 3-arm NCT01394978

NeoMend ProGEL™ Pleural Air Leak Sealant Post-Approval Study

AirTight: A Prospective Controlled Post-Approval Study of NeoMend ProGEL™ Pleural Air Leak Sealant in the Treatment of Visible Pleural Air Leaks After Standard Pleural Closure

Sponsor: C. R. Bard

Updated 8 times since 2017 Last updated: Jul 13, 2021 Started: Jun 30, 2011 Primary completion: Feb 29, 2016 Completion: Feb 29, 2016
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01394978, this NA trial focuses on Lung Cancer and Lung Tumor and remains completed. Sponsored by C. R. Bard, it has been updated 8 times since 2011, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotCompleted~Feb 2017 – ~Aug 2017 · 6 months · monthly snapshotCompleted~Aug 2017 – ~Jun 2018 · 10 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshotCompleted~Sep 2021 – ~Jul 2024 · 34 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 22 months · monthly snapshotCompleted

Change History

8 versions recorded
  1. Sep 2024 — Present [monthly]

    Completed NA

  2. Jul 2024 — Sep 2024 [monthly]

    Completed NA

  3. Sep 2021 — Jul 2024 [monthly]

    Completed NA

  4. Jan 2021 — Sep 2021 [monthly]

    Completed NA

  5. Jun 2018 — Jan 2021 [monthly]

    Completed NA

Show 3 earlier versions
  1. Aug 2017 — Jun 2018 [monthly]

    Completed NA

  2. Feb 2017 — Aug 2017 [monthly]

    Completed NA

  3. Jan 2017 — Feb 2017 [monthly]

    Completed NA

    First recorded

Jun 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • C. R. Bard
Data source: C. R. Bard

For direct contact, visit the study record on ClinicalTrials.gov .